An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice
Authors
Keywords
-
Journal
Science Immunology
Volume 5, Issue 50, Pages eaba5264
Publisher
American Association for the Advancement of Science (AAAS)
Online
2020-08-15
DOI
10.1126/sciimmunol.aba5264
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- De novo design of potent and selective mimics of IL-2 and IL-15
- (2019) Daniel-Adriano Silva et al. NATURE
- An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
- (2019) Kevan C. Herold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
- (2019) Jing He et al. ANNALS OF THE RHEUMATIC DISEASES
- T Regulatory Cells From Non-obese Diabetic Mice Show Low Responsiveness to IL-2 Stimulation and Exhibit Differential Expression of Anergy-Related and Ubiquitination Factors
- (2019) Gloria J. Godoy et al. Frontiers in Immunology
- IL-2 and Beyond in Cancer Immunotherapy
- (2018) John M. Wrangle et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
- (2018) Michelle Rosenzwajg et al. ANNALS OF THE RHEUMATIC DISEASES
- A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease
- (2018) Laurence B. Peterson et al. JOURNAL OF AUTOIMMUNITY
- Reduced interleukin-2 responsiveness impairs the ability of Treg cells to compete for IL-2 in nonobese diabetic mice
- (2016) Cini R James et al. IMMUNOLOGY AND CELL BIOLOGY
- The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes
- (2016) James A. Pearson et al. JOURNAL OF AUTOIMMUNITY
- Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability
- (2016) Frederick W. Jacobsen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
- (2016) Jing He et al. NATURE MEDICINE
- Time-Dependent Regulation of IL-2R α-Chain (CD25) Expression by TCR Signal Strength and IL-2-Induced STAT5 Signaling in Activated Human Blood T Lymphocytes
- (2016) Alla N. Shatrova et al. PLoS One
- Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
- (2015) Caroline von Spee-Mayer et al. ANNALS OF THE RHEUMATIC DISEASES
- Correction
- (2015) ANNALS OF THE RHEUMATIC DISEASES
- Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells
- (2015) Charles J.M. Bell et al. JOURNAL OF AUTOIMMUNITY
- Control of the Inheritance of Regulatory T Cell Identity by a cis Element in the Foxp3 Locus
- (2014) Yongqiang Feng et al. CELL
- Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
- (2014) A. A. Kennedy-Nasser et al. CLINICAL CANCER RESEARCH
- The IL-2 cytokine family in cancer immunotherapy
- (2014) Geok Choo Sim et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata
- (2014) Emeline Castela et al. JAMA Dermatology
- Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2
- (2013) Jonathan Sitrin et al. JOURNAL OF EXPERIMENTAL MEDICINE
- T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
- (2013) Julien Laurent et al. Journal of Translational Medicine
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
- (2011) S. D. Gillies et al. CLINICAL CANCER RESEARCH
- Regulatory T cells and Foxp3
- (2011) Alexander Y. Rudensky IMMUNOLOGICAL REVIEWS
- A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy
- (2011) Simone C Wuest et al. NATURE MEDICINE
- Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
- (2011) David Saadoun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
- (2011) John Koreth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects
- (2009) S. A. Long et al. DIABETES
- Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction
- (2008) Qizhi Tang et al. IMMUNITY
- IL-2 Family of Cytokines in T Regulatory Cell Development and Homeostasis
- (2008) Thomas R. Malek et al. JOURNAL OF CLINICAL IMMUNOLOGY
- The Biology of Interleukin-2
- (2007) Thomas R. Malek Annual Review of Immunology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now